CoChat

A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Eszopiclone 2 mg on Sleep/Wake Function in Older Adults with Primary and Comorbid Insomnia

Open access
Ancoli-lsrael, Sonia, Krystal, Andrew D., McCall, W. Vaughn, Schaefer, Kendyl, Wilson, Amy, Claus, Raymond, Rubens, Robert, Roth, Thomas · 2010 · Sleep
Cited by 96

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Longer-term pharmacologic studies for insomnia in older individuals are sparse. OBJECTIVE: To evaluate the efficacy and safety of 12 weeks of nightly eszopiclone in elderly outpatients with insomnia. METHODS: Participants (65-85 years) met DSM-IV-TR criteria for insomnia with total sleep times (TST) < or = 6 h, and wake time after sleep onset (WASO) > or = 45 min. Participants were randomized to 12 weeks of eszopiclone 2 mg (n = 194) or placebo (n = 194), followed by a 2-week single-blind placebo run-out. Subject-reported measures of sleep (sTST, sleep latency [sSL], sWASO) and daytime function (alertness, concentration, wellbeing, ability to function) were assessed. AEs were monitored. RESULTS: Subjects treated with 2 mg eszopiclone slept longer at night on average and at every individual time point compared to baseline than placebo subjects, as measured by TST over the 12-week double-blind period (P < 0.0001). Mean sTST over the double-blind period for eszopiclone-treated subjects was 360.08 min compared to 297.86 min at baseline, a mean change of 63.24 min. Over the double-blind period, eszopiclone-treated subjects also experienced a significantly greater improvement in sSL compared to placebo, with a mean decrease of 24.62 min versus a mean decrease of 19.92 min, respectively (P = 0.0014). Eszopiclone subjects also experienced a significantly greater decrease in WASO (mean decrease of 36.4 min) compared to placebo subjects (decrease of 14.8 min) (P < 0.0001). Post-discontinuation, sleep parameters were statistically improved versus baseline for eszopiclone (P-values < or = 0.01), indicating no rebound. The most common AEs (> or = 5%) were headache (eszopiclone 13.9%, placebo 12.4%), unpleasant taste (12.4%, 1.5%), and nasopharyngitis (5.7%, 6.2%). CONCLUSION: In this Phase IV trial of older adults with insomnia, eszopiclone significantly improved patient-reported sleep and daytime function relative to placebo. Improvements occurred within the first week and were maintained for 3 months, with no evidence of rebound insomnia following discontinuation. The 12 weeks of treatment were well tolerated. CLINICAL TRIAL INFORMATION: A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly Subjects With Primary Chronic Insomnia; Registration #NCT00386334; URL - http://www.clinicaltrials.gov/ct2/show/NCT00386334?term=eszopiclone&rank=24

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/sleep/33.2.225

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 29

  1. 1999, Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey, I. Sleep, 22, S347
  2. 2005, Prevalence, associated risks, and treatment patterns of insomnia, J Clin Psychiatry, 66, 10
  3. 1999, Sleep Incidence and remission of insomnia among elderly adults: an epidemiologic study of 6,800 persons over three years, Sleep, 22, S366
  4. 2006, Sleep: a marker of physical and mental health in the elderly, Am J Geriatr Psychiatry, 14, 860, 10.1097/01.JGP.0000206164.56404.ba · DOI · Paper page
  5. 2008, Association between depressive symptoms and sleep disturbances in community-dwelling older men, J Am Geriatr Soc, 56, 1228, 10.1111/j.1532-5415.2008.01753.x · DOI · Paper page
  6. 2005, Normative sleep data, cognitive function and daily living activities in older adults in the community, Sleep, 28, 981
  7. 2001, The impact of insomnia on cognitive functioning in older adults, J Am Geriatr Soc, 49, 1185, 10.1046/j.1532-5415.2001.49235.x · DOI · Paper page
  8. 2006, Poor sleep is associated with impaired cognitive function in older women: the study of osteoporotic fractures, J Gerontol: Biol Sci Med Sci, 61, 405, 10.1093/gerona/61.4.405 · DOI · Paper page
  9. 2008, Association between sleep and physical function in older men: the osteoporotic fractures in men sleep study, J Am Geriatr Soc, 56, 1665, 10.1111/j.1532-5415.2008.01846.x · DOI · Paper page
  10. 2003, The problems of sleep for older women: changes in health outcomes, Age Ageing, 32, 123
  11. 2000, Insomnia in the elderly: a review for the primary care practitioner, Sleep, 23, S23
  12. 2005, Insomnia and hypnotic use, recorded in the minimum data set, as predictors of falls and hip fractures in Michigan nursing homes, J Am Geriatr Soc, 53, 955, 10.1111/j.1532-5415.2005.53304.x · DOI · Paper page
  13. 2008, Poor sleep is associated with increased risk of falls in older women, Arch Intern Med, 168, 1768, 10.1001/archinte.168.16.1768 · DOI · Paper page
  14. 2008, Sleep, insomnia and falls in elderly patients, Sleep Med, S1, S18
  15. 2008, Sleep duration associated with mortality in elderly, but not middle-aged, adults in a large US sample, Sleep, 31, 1087
  16. 2009, Self-reported sleep and nap habits and risk of mortality in a large cohort of older women, J Am Geriatr Soc, 57, 604, 10.1111/j.1532-5415.2008.02171.x · DOI · Paper page
  17. 2006, Insomnia comorbidity and impact and hypnotic use by age group in a national survey population aged 16 to 74 years, Sleep, 29, 1391, 10.1093/sleep/29.11.1391 · DOI · Paper page
  18. 1997, Longitudinal trends in late-life insomnia: implications for prescribing, Age Ageing, 26, 179, 10.1093/ageing/26.3.179 · DOI · Paper page
  19. 2009, A compendium of placebo-controlled trials of the risks/benefits of pharmacologic treatments for insomnia: the empirical basis for clinical practice, Sleep Med Rev, 13, 265, 10.1016/j.smrv.2008.08.001 · DOI · Paper page
  20. 2006, A polysomnography study of eszopiclone in elderly patients with insomnia, Curr Med Res Opin, 22, 1633, 10.1185/030079906X112741 · DOI · Paper page
  21. 2005, A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia, Sleep, 28, 720, 10.1093/sleep/28.6.720 · DOI · Paper page
  22. 1992, The MOS 36-Item short-form health survey (SF-36), Conceptual framework and item selection. Med Care, 30, 473
  23. 2007, Frequent napping is associated with excessive daytime sleepiness, depression, pain, and nocturia in older adults: findings from the National Sleep Foundation ‘2003 Sleep in America' Poll, Am J Geriatr Psychiatry, 15, 344, 10.1097/01.JGP.0000249385.50101.67 · DOI · Paper page
  24. 2008, Association between nighttime sleep and napping in older adults, Sleep, 31, 733, 10.1093/sleep/31.5.733 · DOI · Paper page
  25. 2006, Self-reported sleep and nap habits and risk of falls and fractures in older women: the study of osteoporotic fractures, J Am Geriatr Soc, 54, 1177, 10.1111/j.1532-5415.2006.00818.x · DOI · Paper page
  26. NIH State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults statement, 2005, J Clin Sleep Med, 1, 412, 10.5664/jcsm.26373 · DOI
  27. 2005, Prevalence and co-morbidity of insomnia and impact on functioning in elderly populations, J Am Geriatr Soc, 53, S264, 10.1111/j.1532-5415.2005.53392.x · DOI · Paper page
  28. 2007, Nightly treatment of primary insomnia with eszopiclone for six months: Effect on sleep, quality of life, and work limitations, Sleep, 30, 959, 10.1093/sleep/30.8.959 · DOI · Paper page
  29. 1999, Zaleplon, a novel nonbenzodiazepine hypnotic, effectively treats insomnia in elderly patients without causing rebound effects, Prim Care Companion J Clin Psychiatry, 1, 114, 10.4088/PCC.v01n0404 · DOI · Paper page

Cited by

See all 96

Metadata

Authors
Ancoli-lsrael, S., Krystal, A. D., McCall, W. V., Schaefer, K., Wilson, A., Claus, R., Rubens, R., & Roth, T.
Venue
Sleep
Published
2010-02
Volume
33
Issue
2
Pages
225-234
ISSN
  • 0161-8105 (ISSN-L)
  • 1550-9109
OpenAlex
W5483291
Cited by
96
References
11
FWCI
9.59
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Eszopiclone 2 mg on Sleep/Wake Function in Older Adults with Primary and Comorbid Insomnia. https://app.cochat.ai/papers/10.1093/sleep/33.2.225
The paper
Ancoli-lsrael, S., Krystal, A. D., McCall, W. V., Schaefer, K., Wilson, A., Claus, R., Rubens, R., & Roth, T. (2010). A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effect of Eszopiclone 2 mg on Sleep/Wake Function in Older Adults with Primary and Comorbid Insomnia. Sleep. https://doi.org/10.1093/sleep/33.2.225

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.